Beclin-1’s influence extends beyond autophagy regulation, impacting therapeutic outcomes and drug resistance mechanisms in acute promyelocytic leukemia (APL) and chronic myeloid leukemia (CML). Here, BECN1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.